NasdaqGS - Delayed Quote USD

Allogene Therapeutics, Inc. (ALLO)

2.8900 +0.0350 (+1.23%)
At close: April 26 at 4:00 PM EDT
2.9199 +0.03 (+1.03%)
After hours: April 26 at 6:34 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
95.0000
95.0000
156.0000
114,089.0000
--
Operating Expense
314,587.0000
314,587.0000
335,692.0000
294,281.0000
258,243.0000
Operating Income
-314,492.0000
-314,492.0000
-335,536.0000
-180,192.0000
-258,243.0000
Net Non Operating Interest Income Expense
18,307.0000
18,307.0000
4,566.0000
1,714.0000
9,164.0000
Other Income Expense
-31,080.0000
-31,080.0000
-9,444.0000
-3,573.0000
-67,302.0000
Pretax Income
-327,265.0000
-327,265.0000
-340,414.0000
-182,051.0000
-316,381.0000
Net Income Common Stockholders
-327,265.0000
-327,265.0000
-340,414.0000
-182,051.0000
-316,381.0000
Diluted NI Available to Com Stockholders
-327,265.0000
-327,265.0000
-340,414.0000
-182,051.0000
-316,381.0000
Basic EPS
-2.09
--
-2.38
-1.34
-2.63
Diluted EPS
-2.09
--
-2.38
-1.34
-2.63
Basic Average Shares
156,931.7780
--
143,147.1650
135,820.3860
120,370.1770
Diluted Average Shares
156,931.7780
--
143,147.1650
135,820.3860
120,370.1770
Total Operating Income as Reported
-327,737.0000
-327,737.0000
-335,536.0000
-180,192.0000
-258,243.0000
Total Expenses
314,587.0000
314,587.0000
335,692.0000
294,281.0000
258,243.0000
Net Income from Continuing & Discontinued Operation
-327,265.0000
-327,265.0000
-340,414.0000
-182,051.0000
-316,381.0000
Normalized Income
-314,020.0000
-314,020.0000
-340,414.0000
-182,051.0000
-316,381.0000
Interest Income
18,307.0000
18,307.0000
4,566.0000
1,714.0000
9,164.0000
Net Interest Income
18,307.0000
18,307.0000
4,566.0000
1,714.0000
9,164.0000
EBIT
-314,492.0000
-314,492.0000
-335,536.0000
-180,192.0000
-258,243.0000
EBITDA
-300,293.0000
-300,293.0000
-321,241.0000
-169,738.0000
-250,657.0000
Reconciled Depreciation
14,199.0000
14,199.0000
14,295.0000
10,454.0000
7,586.0000
Net Income from Continuing Operation Net Minority Interest
-327,265.0000
-327,265.0000
-340,414.0000
-182,051.0000
-316,381.0000
Total Unusual Items Excluding Goodwill
-13,245.0000
-13,245.0000
--
--
--
Total Unusual Items
-13,245.0000
-13,245.0000
--
--
--
Normalized EBITDA
-287,048.0000
-287,048.0000
-321,241.0000
-169,738.0000
-250,657.0000
12/31/2020 - 10/11/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

FATE Fate Therapeutics, Inc.
3.8000
-1.81%
 
ARQT Arcutis Biotherapeutics, Inc.
8.47
-1.40%
 
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
 
ATRA Atara Biotherapeutics, Inc.
0.6900
-1.40%
 
BLUE bluebird bio, Inc.
0.9228
+1.13%
 
AUTL Autolus Therapeutics plc
4.0000
-1.96%
 
MRSN Mersana Therapeutics, Inc.
2.9400
+3.16%
 
VERV Verve Therapeutics, Inc.
6.16
-0.96%
 
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
 
CLLS Cellectis S.A.
2.5056
+0.63%